Share this article
Share this article
PORTLAND, Ore., Feb. 16, 2021 /PRNewswire/ OCHIN applauds the Biden Administration for prioritizing health equity in a national COVID-19 response by ensuring that vaccines are provided to the nation s federally qualified health centers (FQHCs). This is a crucial step toward ensuring that people of color, who have been disproportionately affected by the pandemic, are not left behind in the race to achieve mass vaccination. Every person should have fair and equitable access to a COVID-19 vaccine through a trusted health care provider, said Abby Sears, CEO at OCHIN. Community health centers are a lifeline in underserved communities. They have the tools and have built the trust to vaccinate those who may be harder to reach, but who stand to benefit most.
EX Program By Truth Initiative® And McLeod Health Join Forces To Help Employees, Patients Live Tobacco Free
With Support from Truth Initiative, the EX® Program Brings Personalized Quit Smoking Tools to the McLeod Health Employee Wellness Program
News provided by
Share this article
from Truth Initiative
®, the national public health organization inspiring lives free from smoking, vaping and nicotine, today announced that it is joining forces with McLeod Health, a leading healthcare network.
The EX Program will be available to the nearly 8,900 employees working for the McLeod Health system of hospitals and physician practices in northeastern South Carolina. The McLeod Healthier You Program will integrate the EX Program into its overall wellness package for employees. With the EX Program, McLeod Health will now provide all employees who use tobacco including smokers with chronic conditions such as diabetes or heart disease tailored support to quit.
Share this article
Share this article
ResearchAndMarkets.com s offering.
Genetic involvement in the pathogenesis of neurological disease is significant. Central nervous system disorders account for approximately 60 percent of the 6,400 phenotypic entries in cataloged inherited human diseases. Neurological diseases, especially brain diseases, are the last frontier in medical discovery. Advances in testing such as next-generation sequencing have been instrumental in identifying genetic causes for neurological conditions.
The area of inherited condition testing for neurological conditions has become a major area of activity in the last decade or so, coinciding with the acceleration of sequencing and other technologies. Increasing awareness of neurological disorders, the aging population, and continued advancements in medical genetics will likely drive the neurological genetic testing market.
Share this article
Share this article
NEW YORK and SECAUCUS, N.J., Feb. 16, 2021 /PRNewswire/ EmblemHealth, one of the nation s largest non-profit health insurers, and Quest Diagnostics (NYSE: DGX), the world s leading provider of diagnostic information services, have renewed their long-standing strategic relationship to provide comprehensive clinical laboratory services for the more than three million members of EmblemHealth and its affiliate, ConnectiCare.
(PRNewsfoto/Quest Diagnostics) We are pleased to renew our long-standing strategic relationship with EmblemHealth, one of the largest non-profit health insurers in the nation, said Steve Rusckowski, Chairman, CEO and President of Quest Diagnostics. As the preferred in-network laboratory for all products, we look forward to continue working to reduce the cost of care, improve member outcomes, and enhance the experience for EmblemHealth and ConnectiCare members.
/PRNewswire/ TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients.